OncoSec Sends Letter to Shareholders Highlighting that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Have Recommended That OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card Jan 06, 2020 8:30am EST
Institutional Shareholder Services Inc. ("ISS") Recommends OncoSec Shareholders Vote “FOR” the CGP/Sirtex Transaction Dec 26, 2019 8:30am EST
OncoSec Releases Presentation Spotlighting the Benefits of the Proposed CGP/Sirtex Transaction and Partnership Dec 20, 2019 9:00am EST
OncoSec to Receive Approximately $885,000 Through New Jersey Technology Business Tax (NOL) Program Dec 16, 2019 8:30am EST
OncoSec Presents Interim Data of 28.5% Objective Response Rate (ORR) from Ongoing KEYNOTE-890 Study Evaluating TAVO™ in Combination with KEYTRUDA® for Heavily Pretreated, Late-Stage, Metastatic Triple Negative Breast Cancer (mTNBC) at the 2019 San Antonio Breast Cancer Symposium Dec 13, 2019 8:30am EST
OncoSec Releases Video Highlighting Why CGP/Sirtex Strategic Transaction Will Create Significant Shareholder Value Dec 09, 2019 8:30am EST
OncoSec to Present Interim Data from Ongoing KEYNOTE-890 Study of TAVO™ and KEYTRUDA® in Late-Stage Metastatic Triple Negative Breast Cancer at the 2019 San Antonio Breast Cancer Symposium Dec 05, 2019 8:30am EST
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing Dec 04, 2019 9:00am EST
